Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label attachment file name title
tabling member	label

Search

77162

registered interest
date	10/07/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how many people in Hemsworth constituency are currently being treated for prostate cancer, what the average waiting time for treatment of such people is; and what steps his Department is taking to raise awareness of prostate cancer.
tabling member constituency	Hemsworth
tabling member printed	Jon Trickett
uin	205102
answer	answer is ministerial correction date of answer 17/07/2014 answer text <p>The information is not available in the format requested. The following table shows the number of finished admission episodes (FAEs) with a primary diagnosis of prostate cancer, and the average time these patients waited in Hemsworth constituency in 2012-13.</p><p> </p><table><tbody><tr><td><p>Year</p></td><td><p>FAEs<sup>1</sup></p></td><td><p>Average time waited (days)<sup>2</sup></p></td><td><p>FAEs with valid waiting time<sup>3</sup></p></td></tr><tr><td><p>2012-13</p></td><td><p>64</p></td><td><p>32.6</p></td><td><p>39</p></td></tr></tbody></table><p> </p><p><em>Source:</em> Hospital Episode Statistics (HES), Health and Social Care Information Centre</p><p> </p><p><em>Notes: </em></p><p>1. An FAE is the first period of admitted patient care under one consultant within one healthcare provider. FAEs are counted against the year or month in which the admission episode finishes. Admissions do not represent the number of patients, as a person may have more than one admission within the period.</p><p>2. Time waited (days) statistics from Hospital Episode Statistics (HES) are not the same as published Referral to Treatment (RTT) time waited statistics. HES provides counts and time waited for all patients between decision to admit and admission to hospital within a given period. Published RTT waiting statistics measure the time waited between referral and start of treatment.</p><p>3. The total number of eligible admissions from which the mean and median time waited are derived. This includes waiting list and booked admissions, but not planned admissions. A waiting list admission is one in which a patient has been admitted electively into hospital from a waiting list, having been given no date of admission at the time a decision to admit was made. Booked admissions are those in which the patient was admitted electively having been given a date at the time it was decided to admit. Planned admissions are excluded as they are usually part of a planned sequence of clinical care determined mainly on clinical criteria, which, for example, could require a series of events, perhaps taking place every three months, six months or annually. It is the case that some providers do not supply the data required to calculate a time waited on eligible episodes.</p><p>4. The parliamentary constituency uses the patient's normal home address. This does not necessarily reflect where the patient was treated as they may have travelled to another parliamentary constituency for treatment.</p><p>Improving Outcomes: A Strategy for Cancer, published in January 2011, committed over £450 million over the four years up to 2014-15 to achieve earlier diagnosis of cancer. This included funding for centrally-led Be Clear on Cancer campaigns, which aim to raise awareness of the symptoms of cancer, get symptomatic patients to present earlier, and work to help support general practitioners (GPs).</p><p>Prostate cancer is challenging from the perspective of driving early diagnosis through a social marketing campaign, as the symptoms of prostate cancer are the same as for other benign prostate disease. However, due to their increased risk, we are actively considering prostate cancer within African-Caribbean men as the subject for a local pilot activity. In addition, awareness is raised through the Prostate Cancer Risk Management Programme, which is in place to ensure that men over 50 without symptoms of prostate cancer can have a prostate specific antigen test free on the national health service after careful consideration of the advantages and disadvantages of the test and after a discussion with a GP.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 17/07/2014 14:03:30 answering member 3918 label Biography information for Jane Ellison
tabling member	410 label Biography information for Jon Trickett

64194

registered interest
date	26/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, how much the Government has spent on prostate cancer research in each of the last five years for which figures are available.
tabling member constituency	Mid Bedfordshire
tabling member printed	Nadine Dorries
uin	202567
answer	answer is ministerial correction date of answer 02/07/2014 answer text <p>The following figures provide an annualised estimate of Government funding for prostate cancer research, provided by the National Cancer Research Institute Cancer Research Database 2009 to 2013.</p><p> </p><table><tbody><tr><td><p> </p></td><td><p>2009</p><p>£</p></td><td><p>2010</p><p>£</p></td><td><p>2011</p><p>£</p></td><td><p>2012</p><p>£</p></td><td><p>2013</p><p>£</p></td></tr><tr><td><p>Prostate Cancer</p></td><td><p>7,895,544</p></td><td><p>7,158,048</p></td><td><p>7,095,581</p></td><td><p>9,484,685</p></td><td><p>8,276,039</p></td></tr></tbody></table><p> </p><p>These figures include only direct spend on prostate cancer research, or spend which directly supports prostate cancer research; it does not include fundamental research that could have implications for prostate cancer in the longer term.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 02/07/2014 15:39:41 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1481 label Biography information for Ms Nadine Dorries

64195

registered interest
date	26/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to ensure the same standard of care across the country for those diagnosed with prostate cancer.
tabling member constituency	Mid Bedfordshire
tabling member printed	Nadine Dorries
uin	202568
answer	answer is ministerial correction date of answer 03/07/2014 answer text <p>To help reduce regional variations, the Care Quality Commission (CQC) is increasingly incorporating information from accreditation and peer review programmes into its assessments of National Health Service trusts' services, including the National Cancer Peer Review Programme. The CQC also intends to use data from the national clinical audit which is being developed for prostate cancer. In addition, national statistics on waiting times experienced by patients with suspected and diagnosed cancers continue to be collected, monitored and published in order to improve equity of access to cancer services and to contribute to an improvement in survival rates.</p><p> </p><p>The results of the latest national Cancer Patient Experience Survey (CPES) from 2013 show that, whilst variations between trusts still exist, the overall range of variation for many indicators has narrowed. For example, in 2010 the proportion of patients saying that they had been given the name of a Clinical Nurse Specialist ranged from 92% in the highest performing trust to 59% in the poorest performing trust (33 points); by 2013 this had reduced to 97% to 76% (21 points).</p><p> </p><p>NHS Improving Quality (NHS IQ) will be doing a suite of work across all surveys to understand what the barriers are to implementing change and to showcase best practice where real improvements can be demonstrated.</p><p> </p><p>NHS England is working with NHS IQ to develop better ways of using the CPES data within the NHS in order to maximise the impact of the survey, to be able to work with successful and struggling organisations to spread best practice for example.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 03/07/2014 13:10:58 answering member 3918 label Biography information for Jane Ellison
tabling member	1481 label Biography information for Ms Nadine Dorries

64196

registered interest
date	26/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will include prostate cancer in the next Be Clear on Cancer awareness campaign; and if he will make a statement.
tabling member constituency	Mid Bedfordshire
tabling member printed	Nadine Dorries
uin	202569
answer	answer is ministerial correction date of answer 03/07/2014 answer text <p>Be Clear on Cancercampaigns are tested at a local and regional level, before a decision is taken on whether to run them nationally throughout England.</p><p> </p><p>Public Health England is actively considering potential local pilot activity specifically targeting prostate cancer within Black African-Caribbean men, due to their significantly increased risk of developing prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 03/07/2014 13:12:42 answering member 3918 label Biography information for Jane Ellison
tabling member	1481 label Biography information for Ms Nadine Dorries

61736

registered interest
date	12/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, if he will take steps to prevent NHS England from implementing restrictions on the use of new drugs for advanced prostate cancer, enzalutamide and abiraterone.
tabling member constituency	Stoke-on-Trent South
tabling member printed	Robert Flello
uin	200514
answer	answer is ministerial correction date of answer 17/06/2014 answer text <p>The National Institute for Health and Care Excellence (NICE) published technology appraisal guidance in June 2012 which recommends abiraterone (Zytiga) in its licensed indication for the treatment of castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen, subject to a patient access scheme agreed between the Department and the drug's manufacturer.</p><p> </p><p>NICE is currently appraising (i) abiraterone for the treatment of metastatic hormone relapsed prostate cancer not previously treated with chemotherapy and (ii) enzalutamide for metastatic hormone-relapsed prostate cancer in adults whose disease has progressed during or after docetaxel-containing chemotherapy.</p><p> </p><p>National Health Service commissioners are legally required to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>In the absence of NICE technology appraisal guidance it is for the relevant NHS commissioner to make funding decisions based on an assessment of the available evidence. The NHS Constitution states that patients have the right to expect local decisions on the funding of drugs and treatments 'to be made rationally following a proper consideration of the evidence'.</p><p> </p><p>We understand that abiraterone as a first-line treatment is available through the Cancer Drugs Fund to NHS patients in England who could benefit from it, and that enzalutamide is also available through the Cancer Drugs Fund to patients who meet specified clinical criteria.</p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 17/06/2014 14:13:43 answering member 1439 label Biography information for Norman Lamb
tabling member	1569 label Biography information for Robert Flello

58513

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199302
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58514

registered interest
date	05/06/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many people died from prostate cancer in (a) Plymouth, Sutton and Devonport constituency and (b) England in each of the last five years.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199306
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p><p> </p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 10/06/2014 12:48:36 answering member 1561 label Biography information for Mr Nick Hurd attachment 1 file name PQ 199306.pdf title ONS Letter to Member
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58516

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment his Department has made of outcomes for men with advanced prostate cancer.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199304
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199303 question first answered 10/06/2014 15:28:11 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58108

registered interest
date	04/06/2014
answering body	Cabinet Office
answering dept id	53
answering dept short name	Cabinet Office
answering dept sort name	Cabinet Office
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Minister for the Cabinet Office, how many men have been diagnosed with prostate cancer in each of the last five years.
tabling member constituency	Huddersfield
tabling member printed	Mr Barry Sheerman
uin	199035
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The information requested falls within the responsibility of the UK Statistics Authority. I have asked the Authority to reply.</p><p> </p> answering member constituency Ruislip, Northwood and Pinner answering member printed Mr Nick Hurd question first answered 10/06/2014 15:04:21 answering member 1561 label Biography information for Mr Nick Hurd attachment 1 file name PQ 199035.pdf title ONS Letter to Member
tabling member	411 label Biography information for Mr Barry Sheerman